Braf
A gene whose mutations drive several cancers; a major target for precision drugs.
If Braf is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial · Journal of Clinical Oncology · 2026-08-30
- WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer. · Gastroenterology · 2026-08-18
- Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer. · iScience · 2026-08-13
- Cost-effectiveness analysis of triplet therapy of encorafenib, binimetinib, and cetuximab for treatment of metastatic BRAF V600E-mutated colorectal cancer in China. · Front Pharmacol · 2026-08-10
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
- Successful Encorafenib and Cetuximab Re-Challenge Combined With Nivolumab in BRAF V600E Mutated, Mismatch-Repair-Proficient Metastatic Colorectal Cancer – A Case Report From the AGMT mCRC Registry · Clinical Colorectal Cancer · 2026-08-02
What the reporting says
It shows up alongside Colorectal Cancer (69), Braf V600e (32), Egfr (20 — acquisition ×2), KRAS (16 — acquisition ×2), Immunotherapy (8).
Two steps out: ctDNA (through Colorectal Cancer, 69 shared stories on the weaker link); Wang (through Colorectal Cancer, 63 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 53 shared stories on the weaker link); Chen (through Colorectal Cancer, 45 shared stories on the weaker link).
Tracked since Mar 15, with coverage on 70 separate days — concentrated in Oncology and Pubmed Targeted.